600085 Beijing Tongrentang
- 42.04
- -0.61-1.43%
Beijing Tongrentang News
Tong Ren Tang Technology (01666): Feng Zhimei has been appointed as an executive director.
Zhitong Finance and Economics APP reported that Tong Ren Tang Technology (01666) announced that, effective June 12, 2024, (i) Di Shubing, Chen Jiafu and Feng Zhimei were appointed as executive directors of the ninth Board of Directors; (ii) Zhang Yi, Wang Chunrui and Feng Li were appointed as non-executive directors of the ninth Board of Directors; and (iii) Chen Qingxia, Zhan Yuanjing, and Li Zhaobin were appointed as independent non-executive directors of the ninth Board of Directors. Effective June 12, 2024, Guo Wen and Wu Yigang were appointed as shareholder representative supervisors of the ninth Supervisor Board. At the same time, the workers' representative group held on May 14, 2024
Tong Ren Tang Technology (01666) will pay a final dividend of $0.18 per share on August 9
According to Zhitong Finance App, Tong Ren Tang Technology (01666) announced that the company will pay a final dividend of RMB 0.18 per share on August 9, 2024.
China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly
The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.
Tong Ren Tang Technology (01666) proposes to appoint Zhang Yi as a non-executive director
Tong Ren Tang Technology (01666) announced that since the term of the 8th board of directors will expire at the end of the annual general meeting of shareholders, Dong...
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 24
According to the Zhitong Finance App, Tong Ren Tang Sinopharm (03613) announced that it will pay a final dividend of HK$0.33 per share for the year ended 31 December 2023 on June 24, 2024.
Tong Ren Tang Sinopharm (03613.HK) appoints Wang Chi as CEO
Gelonghui, May 10, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that Mr. Wang Chi was appointed as the company's executive director, CEO and member of the Competition Executive Committee, effective May 10, 2024. The board of directors further announced that since Mr. Wang was appointed as the company's CEO, Mr. Chen Fei, executive director, acting CEO and executive deputy general manager of the company will no longer serve as acting CEO. Effective May 10, 2024, he will continue to serve as the company's executive director and executive deputy general manager.
Tong Ren Tang Chinese Medicine (03613.HK): “Angelica Blood Supplement Granules [Tong Ren Tang]” approved for sale in Hong Kong
Gelonghui, April 30, 丨 Tong Ren Tang Chinese Medicine (03613.HK) announced that the company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, permitting the sale of “Angelica Supplementation Granules [Tong Ren Tang]” in Hong Kong. The relevant information notice is as follows: Drug Name: Angelica Blood Supplementation Granules [Tong Ren Tang]; Registered Holder and Address: Beijing Tong Ren Tang Sinopharm Co., Ltd., No. 3, Da Jing Street, Tai Po Industrial Estate, New Territories, Hong Kong; registration number: HKC-18604; certificate validity period: until April 25, 2029.” The main function of “Angelica Blood Supplementation Granules [Tong Ren Tang]”
Tong Ren Tang Chinese Medicine (03613): Issued a certificate of registration for proprietary Chinese medicines
According to Zhitong Finance App, Tong Ren Tang Sinopharm (03613) issued an announcement. The company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, which allows the sale of “Angelica Blood Supplementation Granules [Tong Ren Tang]” in Hong Kong.
Stable sector+product space, Tongrentang Technology (01666.HK)'s dual market potential
As we all know, in the Hong Kong stock market, Chinese medicine stocks have been undervalued for a long time. Judging from the net market ratio, the net market ratio of the entire traditional Chinese medicine concept is less than 1 times. A large part of the reason behind this is that investors in the Hong Kong stock market, especially foreign investors, have long had no understanding of traditional Chinese medicine or traditional Chinese medicine, and even misunderstood the introduction of animals and plants into medicine.
Invisible stocks released! Zhang Kun: Striving for Miracles” and “Black Chicken Becomes Phoenix” are over
On March 29, Zhang Kun, manager of E-Fangda's ace fund manager, released the annual report.
Tong Ren Tang Sinopharm (03613): Chen Fei appointed as acting CEO
Tong Ren Tang Sinopharm (03613) announced that Yu Jin has resigned as the company's executive director and CEO due to personal matters...
Tung Yan Tong Technology Announces 2023 Annual Results
BEIJING, MARCH 25, 2024 /NEWS MEDIA/ -- BEIJING TONGRENTANG TECHNOLOGY DEVELOPMENT CO., LTD. (“TONG YANTANG TECHNOLOGY” OR THE “GROUP”, 1666.HK) IS PLEASED TO ANNOUNCE THE GROUP'S AUDITED CONSOLIDATED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013. In 2013, the Group achieved revenues of RMB67.7 billion, an increase of 13.04% year-on-year; achieved net net income of RMB5.9 billion, an increase of 1.25% year-on-year; in terms of products, the Group sold 62 products of more than RMB 500 million and sales of more than RMB 1 billion.
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
Tongrentang Technology (01666.HK)'s 2023 revenue of 6.773 billion yuan increased 13.04% year-on-year
Gelonghui, March 22丨Tong Ren Tang Technology (01666.HK) announced that for the year ended December 31, 2023, the Group's revenue was RMB 6.773 billion, up 13.04% year on year; net profit attributable to company owners was RMB 590 million, up 1.25% over the same period last year; earnings per share was RMB 0.46 (2022: RMB 0.46); and dividend per share was RMB 0.18 (2022: RMB 0.16). Throughout the year, the Group is committed to adapting to the new normal in the traditional Chinese medicine industry, continuing to focus on core competitive advantages, and advancing
Tongrentang Technology (01666) announced annual results. Profit attributable to shareholders of 590 million yuan increased 1.25% year-on-year, and final dividend of 0.18 yuan per share
Tong Ren Tang Technology (01666) announced its annual results for the year ended December 31, 2023. The group obtained revenue of RMB 6.773 billion (same unit), an increase of 13.04% year on year; profit attributable to company owners of RMB 590 million, an increase of 1.25% year on year; earnings per share of 0.46 yuan, and plans to pay a final dividend of RMB 0.18 per share.
Damo: Maintaining Tong Ren Tang Sinopharm's (03613) “Gain” Rating and Lowering the Target Price to HK$15
According to the optimistic hypothesis, Tongrentang Sinopharm (03613) sales growth is 20% or more per year.
Tong Ren Tang Sinopharm Announces 2023 Annual Results Profit attributable to shareholders of HK$540 million, a decrease of 16.3% year-on-year
Tong Ren Tang Sinopharm (03613) announced its results for the year ended December 31, 2023. The group achieved revenue of HK$1,525 million, a year-on-year decrease of 11.9%; profit attributable to company owners of HK$540 million, a year-on-year decrease of 16.3%; basic profit per share of HK$0.65; and proposed to pay a final dividend of HK$0.33 per common share.
Tong Ren Tang Sinopharm will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of HK$0.33 per share on June 17, 2024.
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of 0 per share on June 17, 2024...
Tong Ren Tang Sinopharm (03613) announced 2023 annual results. Profit attributable to shareholders of HK$540 million decreased by 16.3% year-on-year
Tongrentang Sinopharm (03613) announced its annual results for the year ended December 31, 2023, and the group achieved acceptance during the period...
Analysis
Price Target
No Data
